Introduction Heart failure (HF) remains a leading cause of morbidity and mortality, accompanied by high rates of (re)-hospitalization, which contribute substantially to its burden on healthcare systems.1, 2 Therefore, developing strategies to alter the natural history of HF, improve clinical outcomes, and reduce HF hospitalizations (HFHs) has been a main point of contemporary research.3 One such innovation is the CardioMEMS™ HF System (Abbott Laboratories, Abbott Park, IL, USA), a pulmonary...